Drug intelligence / Profile preview

Janssen Research & Development EP3 compound 7

Development stage: Unknown
Lead developer: Janssen Research & Development

Overview

Janssen Research & Development EP3 compound 7: sourced facts only. name: "The initial lead compound 7 exhibited potent in vitro EP3 inhibitory activity and good selectivity against other EP receptors." [PMID:35059130]; target: "The initial lead compound 7 exhibited potent in vitro EP3 inhibitory activity and good selectivity against other EP receptors." [PMID:35059130]; developer: "Discovery Chemistry and Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States." [PMID:35059130]; stage: "In addition, compound 7 demonstrated in vivo activity in a rat ivGTT model, reversing the suppressive effect of the EP3-specific agonist sulprostone on glucose-stimulated insulin secretion." [PMID:35059130]

Targets

PTGER3 (Prostaglandin E2 receptor EP3 subtype)

Beyond the preview

Go deeper on Janssen Research & Development EP3 compound 7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Janssen Research & Development EP3 compound 7.